Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection.
Cosenza
C A
CA
Department of Surgery, Cedars-Sinai Research Institute, Cedars-Sinai Medical Center, Los Angeles, California 90211.
Cramer
D V
DV
Eiras-Hreha
G
G
Cajulis
E
E
Wang
H K
HK
Makowka
L
L
D000818:Animals; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D010835:Phytohemagglutinins / Q000494:pharmacology; D051381:Rats; D011917:Rats, Inbred Lew; D013268:Stimulation, Chemical; D014184:Transplantation, Homologous; D011798:Quinaldines
D001713:Biphenyl Compounds; D016572:Cyclosporine; D007166:Immunosuppressive Agents; D010835:Phytohemagglutinins; C046943:brequinar; D011798:Quinaldines